Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice
Alexandra Kuznetsova, Yue Yu, Jennifer Hollister-Lock, Lynn Opare-Addo, Aldo Rozzo, Marianna Sadagurski, Lisa Norquay, Jessica E. Reed, Ilham El Khattabi, Susan Bonner-Weir, Gordon C. Weir, Arun Sharma, Morris F. White
Alexandra Kuznetsova, Yue Yu, Jennifer Hollister-Lock, Lynn Opare-Addo, Aldo Rozzo, Marianna Sadagurski, Lisa Norquay, Jessica E. Reed, Ilham El Khattabi, Susan Bonner-Weir, Gordon C. Weir, Arun Sharma, Morris F. White
View: Text | PDF
Research Article Endocrinology Metabolism

Trimeprazine increases IRS2 in human islets and promotes pancreatic β cell growth and function in mice

  • Text
  • PDF
Abstract

The capacity of pancreatic β cells to maintain glucose homeostasis during chronic physiologic and immunologic stress is important for cellular and metabolic homeostasis. Insulin receptor substrate 2 (IRS2) is a regulated adapter protein that links the insulin and IGF1 receptors to downstream signaling cascades. Since strategies to maintain or increase IRS2 expression can promote β cell growth, function, and survival, we conducted a screen to find small molecules that can increase IRS2 mRNA in isolated human pancreatic islets. We identified 77 compounds, including 15 that contained a tricyclic core. To establish the efficacy of our approach, one of the tricyclic compounds, trimeprazine tartrate, was investigated in isolated human islets and in mouse models. Trimeprazine is a first-generation antihistamine that acts as a partial agonist against the histamine H1 receptor (H1R) and other GPCRs, some of which are expressed on human islets. Trimeprazine promoted CREB phosphorylation and increased the concentration of IRS2 in islets. IRS2 was required for trimeprazine to increase nuclear Pdx1, islet mass, β cell replication and function, and glucose tolerance in mice. Moreover, trimeprazine synergized with anti-CD3 Abs to reduce the progression of diabetes in NOD mice. Finally, it increased the function of human islet transplants in streptozotocin-induced (STZ-induced) diabetic mice. Thus, trimeprazine, its analogs, or possibly other compounds that increase IRS2 in islets and β cells without adverse systemic effects might provide mechanism-based strategies to prevent the progression of diabetes.

Authors

Alexandra Kuznetsova, Yue Yu, Jennifer Hollister-Lock, Lynn Opare-Addo, Aldo Rozzo, Marianna Sadagurski, Lisa Norquay, Jessica E. Reed, Ilham El Khattabi, Susan Bonner-Weir, Gordon C. Weir, Arun Sharma, Morris F. White

×

Figure 6

Effect of trimeprazine on β cell function in Irs2–/– mice.

Options: View larger image (or click on image) Download as PowerPoint
Effect of trimeprazine on β cell function in Irs2–/– mice.
(A) Cox regre...
(A) Cox regression analysis of diabetes onset (random blood glucose >200 mg/dl) in 15 Irs2–/– or control male mice treated without (saline, black line) or with 10 mg/kg trimeprazine (red line) once a day starting at 5 weeks of age until diabetes was diagnosed or the mice reached 16 weeks of age. (B) Control (n = 8) or Irs2–/– (n = 8) mice were treated for 3 weeks with or without 10 mg/kg trimeprazine, and pancreas sections were immunostained with Abs against insulin or stained with DAPI. (C) Two pancreatic sections were analyzed for each mouse, and at least 4 mice were analyzed in each experimental group to determine the percentage of β cell area. The horizontal black bar in the box shows the median, and a GLM (IBM SPSS, version 23) was used to obtain Bonferroni-corrected P values, with genotype and treatment as interacting factors. (D) BrdU incorporation in pancreas sections from 9-week-old control or Irs2–/– mice treated between 6 and 9 weeks of age with or without daily trimeprazine (10 mg/kg). (E) Two pancreatic sections (10 × 10 tiles) were analyzed for each mouse, and at least 4 mice were analyzed for each group to determine the percentage of BrdU-positive β cells against the total number of insulin-positive β cells. The black horizontal bar in the box shows the median, and a GLM was used to obtain the Bonferroni-corrected P values, with genotype and treatment as interacting factors. (F) Control or Irs2–/– mice were treated for 3 weeks with or without trimeprazine. Multiple pancreas sections from 2 or 3 mice in each experimental group were used to calculate Pdx1>MED (see Supplemental Table 2 and the Methods). Box plots show the distribution of Pdx1>MED, and a GLM was used to obtain the Bonferroni-corrected P values, with genotype and treatment as interacting factors. Cntr, control; Sal, saline; Trimep, trimeprazine.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts